Analysing all available prostate cancer datasets in the cBio-portal (n = 22), altered JMJD6 gene was detected in multiple cohorts, with the highest incidence of genetic abnormalities (up to 8%) detected in metastatic tumours (Figure S3). This evidence concerns the gene JMJD6 and prostate carcinoma.